F. Rytz, A. Poellinger, S. Berezowska, T. Geiser, M. Funke-Chambour
{"title":"吡非尼酮治疗石棉相关肺纤维化?回顾性病例系列","authors":"F. Rytz, A. Poellinger, S. Berezowska, T. Geiser, M. Funke-Chambour","doi":"10.1183/13993003.CONGRESS-2018.PA2993","DOIUrl":null,"url":null,"abstract":"Pirfenidone is an established treatment for idiopathic pulmonary fibrosis (IPF). The efficacy in other fibrotic lung diseases has not been tested so far. Asbestos-related lung disease can manifest with inflammation and progressive lung fibrosis with currently no approved treatment option. Pirfenidone with its anti-inflammatory and antifibrotic effects might represent a possible drug treatment. As differentiating between IPF and asbestos-related disease is difficult, patients with a UIP-pattern and signs of asbestos-related disease were retrospectively analyzed within the idiopathic interstitial pneumonia-cohort study. Signs for asbestos-related disease included significant exposure in all patients, pleural plaques in 3/4 patients, presence of asbestos fibres in bronchoalveolar lavage or tissue in 2/4 patients. All 4 patients showed progressive fibrosis within 6 months prior to treatment with a mean decline in forced vital capacity (FVC) of 325 +/- 200 ml. They were subsequently treated with Pirfenidone (3x801mg/day). All patients showed stabilization or even improvement of FVC after 3-6 months of Pirfenidone treatment. Increase of FVC after 6 months was in average +173 +/- 220ml. Side effects were comparable to observed side effects in IPF (nausea, weight loss, phototoxicity) and led to dose reduction in 2 patients (3x534mg/day). In conclusion, this retrospective case series suggest that treatment with Pirfenidone in patients with possible asbestos-related progressive lung fibrosis is well tolerated and resulted in stabilization or even improvement of FVC. Nevertheless, these retrospective findings require confirmation in randomized, placebo-controlled prospective trials.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"90 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series\",\"authors\":\"F. Rytz, A. Poellinger, S. Berezowska, T. Geiser, M. Funke-Chambour\",\"doi\":\"10.1183/13993003.CONGRESS-2018.PA2993\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pirfenidone is an established treatment for idiopathic pulmonary fibrosis (IPF). The efficacy in other fibrotic lung diseases has not been tested so far. Asbestos-related lung disease can manifest with inflammation and progressive lung fibrosis with currently no approved treatment option. Pirfenidone with its anti-inflammatory and antifibrotic effects might represent a possible drug treatment. As differentiating between IPF and asbestos-related disease is difficult, patients with a UIP-pattern and signs of asbestos-related disease were retrospectively analyzed within the idiopathic interstitial pneumonia-cohort study. Signs for asbestos-related disease included significant exposure in all patients, pleural plaques in 3/4 patients, presence of asbestos fibres in bronchoalveolar lavage or tissue in 2/4 patients. All 4 patients showed progressive fibrosis within 6 months prior to treatment with a mean decline in forced vital capacity (FVC) of 325 +/- 200 ml. They were subsequently treated with Pirfenidone (3x801mg/day). All patients showed stabilization or even improvement of FVC after 3-6 months of Pirfenidone treatment. Increase of FVC after 6 months was in average +173 +/- 220ml. Side effects were comparable to observed side effects in IPF (nausea, weight loss, phototoxicity) and led to dose reduction in 2 patients (3x534mg/day). In conclusion, this retrospective case series suggest that treatment with Pirfenidone in patients with possible asbestos-related progressive lung fibrosis is well tolerated and resulted in stabilization or even improvement of FVC. Nevertheless, these retrospective findings require confirmation in randomized, placebo-controlled prospective trials.\",\"PeriodicalId\":178396,\"journal\":{\"name\":\"ILD/DPLD of known origin\",\"volume\":\"90 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ILD/DPLD of known origin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2993\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ILD/DPLD of known origin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2993","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series
Pirfenidone is an established treatment for idiopathic pulmonary fibrosis (IPF). The efficacy in other fibrotic lung diseases has not been tested so far. Asbestos-related lung disease can manifest with inflammation and progressive lung fibrosis with currently no approved treatment option. Pirfenidone with its anti-inflammatory and antifibrotic effects might represent a possible drug treatment. As differentiating between IPF and asbestos-related disease is difficult, patients with a UIP-pattern and signs of asbestos-related disease were retrospectively analyzed within the idiopathic interstitial pneumonia-cohort study. Signs for asbestos-related disease included significant exposure in all patients, pleural plaques in 3/4 patients, presence of asbestos fibres in bronchoalveolar lavage or tissue in 2/4 patients. All 4 patients showed progressive fibrosis within 6 months prior to treatment with a mean decline in forced vital capacity (FVC) of 325 +/- 200 ml. They were subsequently treated with Pirfenidone (3x801mg/day). All patients showed stabilization or even improvement of FVC after 3-6 months of Pirfenidone treatment. Increase of FVC after 6 months was in average +173 +/- 220ml. Side effects were comparable to observed side effects in IPF (nausea, weight loss, phototoxicity) and led to dose reduction in 2 patients (3x534mg/day). In conclusion, this retrospective case series suggest that treatment with Pirfenidone in patients with possible asbestos-related progressive lung fibrosis is well tolerated and resulted in stabilization or even improvement of FVC. Nevertheless, these retrospective findings require confirmation in randomized, placebo-controlled prospective trials.